Expression of TPX2 in esophageal gastric junction adenocarcinoma and its clinical significance

Abstract

Objective To investigate the expression of TPX2 in esophageal gastric junction adenocarcinoma and its clinic significance. Methods Immunohistochemistry was used to detect the expression of TPX2 protein in 80 cases of esophageal gastric junction adenocarcinoma, 41 cases of adjacent atypical hyperplasia tissues and 48 cases of normal gastric mucosa tissues. RT-PCR was adopted to determine the expression of TPX2 mRNA in 40 cases of esophageal gastric junction adenocarcinoma, 36 cases of adjacent atypical hyperplasia tissues and 28 cases of normal gastric mucosa tissues. Results The positive rates of TPX2 protein expression in esophageal gastric junction adenocarcinoma, adjacent atypical hyperplasia tissues and normal gastric mucosa tissues were 71.2% (57/80), 53.7% (22/41) and 31.2% (15/48), respectively, and there were significant differences among them(χ2=10.315, P=0.018). The positive rates of TPX2 mRNA expression were 77.5%(31/40), 69.4%(25/36) and 7.1%(2/28), respectively, and there were significant differences among them(χ2=7.468, P=0.025). The positive rates of expression of TPX2 protein and mRNA in esophageal gastric junction adenocarcinoma increased with the infiltration depth, lymph node metastasis and tumor staging(P 0.05). Conclusions The abnormal expression of TPX2 may be involved in early carcinogenesis, infiltration and metastasis of esophageal gastric junction adenocarcinoma, and the detection of TPX2 expression may play an important role in the early diagnosis and prognosis prediction in patients with esophageal gastric junction adenocarcinoma. Key words: TPX2; Esophageal gastric junction adenocarcinoma; RT-PCR; Immunohistochemistry